Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 425-434

  Messenger, Wyatt B ^a   Beardsley, Robert M ^a   Flaxel, Christina J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Anti VEGF; Dexamethasone; Diabetic macular edema; Fuocinolone; Triamcinolone

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; GLYCOLIC ACID; LACTIC ACID; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; DRUG IMPLANT; VASCULOTROPIN A;

ANTERIOR EYE CHAMBER DISEASE; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE IRRITATION; EYE PAIN; EYE TOXICITY; GLAUCOMA; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; LACRIMATION; LASER COAGULATION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA TEAR; REVIEW; RISK REDUCTION; SIDE EFFECT; SLOW RELEASE FORMULATION; VISUAL ACUITY; VITRECTOMY; ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; DRUG EFFECTS; DRUG IMPLANT; MACULAR EDEMA; PSYCHOLOGY;

DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; HUMANS; INTRAOCULAR PRESSURE; LIGHT COAGULATION; MACULAR EDEMA; QUALITY OF LIFE; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84878345972     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S44427     Document Type: Review

References (60)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf. Accessed May 12, 2013.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527-532.
3. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004;49(5):470-490.
4. Gardner T W, Sander B, Larsen ML, et al. An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial. Curr Eye Res. 2006;31(6):535-547.
5. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-fve-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503.
6. Ferris FL, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28 Suppl:S452-S461.
7. Yau J W, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.
8. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150(2):523-531.
9. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1-29.
10. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999;14(4):233-239.
11. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis A P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158(1):147-152.
12. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner T W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463-23467.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. Erratum in: Lancet. 1999;354(9178):602.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
15. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12): 1796-1806.
16. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmolog y. 2011;118(4):615-625.
17. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110(8): 1155-1159.
18. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5): 920-927.
19. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533-1538.
20. Jonas JB, Kreissig I, Söfker A, Degenring R F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121(1):57-61.
21. Lam DS, Chan CK, Mohamed S, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol. 2007;91(2):199-203.
22. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115(9):1447-1449.
23. Kim JE, Pollack JS, Miller DG, Mittra RA, Spaide RF; Isis Study Group. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina. 2008;28(5):735-740.
24. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes [review]. Cochrane Database Syst Rev. 2008;1:CD005656.
25. Steijns D, Duijvesz D, Breedijk MA, van der Heijden GJ. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol. 2010;88(4):389-393.
26. Kwak H W, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259-266.
27. Scholes GN, O'Brien WJ, Abrams G W, Kubicek MF. Clearance of triam-cinolone from vitreous. Arch Ophthalmol. 1985;103(10):1567-1569.
28. Kuppermann BD, Blumenkranz MS, Haller JA, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intrav-itreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309-317.
29. Haller JA, Kuppermann BD, Blumenkranz MS, et al; Dexametha-sone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289-296.
30. Aiello L P. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2000;353(8):839-841.
31. Cunningham ET, Adamis A P, Altaweel M, et al; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747-1757.
32. Arevalo J F, Fromow-Guerra J, Quiroz-Mercado H, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmolog y. 2007;114(4):743-750.
33. Diabetic Retinopathy Clinical Research Network; Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-1867.
34. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macu-lar photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27(9):1187-1195.
35. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevaci-zumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18(6):941-948.
36. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4): 789-801.
37. Massin P, Bandello F, Garweg JG, et al. Safety and effcacy of ranibi-zumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
38. Nguyen QD, Shah SM, Khwaja AA, et al; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-2151.
39. Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello L P, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmolog y. 2010;117(6):1064-1077.
40. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972-979.
41. Arevalo J F, Lasave AF, Wu L, et al; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 Months. Retina. 2013;33(2):403-413.
42. Do D V, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658-1665.
43. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011;31(8):1449-1469.
44. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema [review]. Cochrane Database Syst Rev. 2012;12:CD007419.
45. Nasrallah F P, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95(10):1335-1339.
46. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99(5):753-759.
47. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130(2):178-186.
48. Harbour J W, Smiddy WE, Flynn HW, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121(4):405-413.
49. Ikeda T, Sato K, Katano T, Hayashi Y. Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol. 1999;83(1):12-14.
50. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27(5):557-566.
51. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):630-637.
52. Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2009;29(4):464-472.
53. Flaxel CJ, Edwards AR, Aiello L P, et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina. 2010; 30(9):1488-1495.
54. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224 Suppl 1: S46-S53.
55. Fluocinolone acetonide ophthalmic-Bausch and Lomb: fuocinolone actinide Envision TD implant. Drugs R D. 2005;6(2):116-119.
56. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118(8): 1580-1587.
57. Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: a 3-year results of a multi-center clinical trial. Invest Ophthalmol Vis Sci. 2006;47:E-Abstract 5442.
58. Campochiaro PA, Hafz G, Shah SM, et al; Famous Study Group. Sustained ocular delivery of fuocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117(7):1393-1399.
59. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Long-term benefit of sustained-delivery fuocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4): 626-635.
60. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Sustained delivery fuocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.